Event Marks One-Year Anniversary of US Supreme Court Decision to Ban Human Gene Patenting
SAN DIEGO, CA – June 17, 2014 – Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, last week co-hosted a fundraiser benefiting Susan G. Komen. Jim Plante, founder and CEO of Pathway Genomics, and Ryan Kavanaugh, CEO of Relativity, were the hosts of the event, titled Pathway to the Cure. The fundraiser, held in Santa Monica, California, raised more than $300,000 through generous donations made by attendees of the event.
“We’re working with Susan G. Komen to help spread awareness about breast cancer, and to help as many women as we can in the battle against this disease,” said Plante. “We’re truly working to save lives, and ultimately prevent breast cancer forever.”
Attended by notable celebrities, such as Adrian Grenier and Sophia Bush, the event’s entertainment for the evening was provided by DJ Zen Freeman and DJ Nikki Pennie, and included a musical performance by world-renowned artist Kesha, whose hits include “Tik Tok,” and the wildly popular “Timber,” a collaboration with rapper Pitbull.
“This was an extraordinary event. We are grateful for the commitment and generosity of supporters such as Relativity and Pathway Genomics that will help us save lives in California and around the world, ” said Susan G. Komen president and CEO, Judith A. Salerno, M.D., M.S.
The fundraiser comes at the one-year anniversary of the U.S. Supreme Court’s unanimous decision to ban the patenting of naturally occurring genes, such as BRCA, the gene linked to breast cancer.
“We firmly believe that genetic testing for the risk of breast cancer is every person’s right and should not be overpriced and monopolized by massive corporations,” said Plante. “Pathway’s BRCA test price and our BRCA One for One program is a testament to this dedication to serve those who cannot afford this potentially life-saving test.”
Earlier this month, Pathway Genomics launched its next-generation sequencing and deletion/duplication analysis, BRCATrueTM, which can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry. To enhance the accessibility of the test, the company also launched the first-of-its-kind BRCA One for OneTM program – for every qualified BRCATrue test ordered, one test is donated to a person in need through patient advocacy organizations, up to $10 million of free testing.